Azafenidin

DB19031InvestigationalSmall molecule

Azafenidin is under investigation in clinical trial NCT01726582 (Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")).

Formula / weight: C₁₅H₁₃Cl₂N₃O₂ · 338.19 g/mol (avg)
Also known as: 2-(2,4-dichloro-5-(2-propynyloxy)phenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one · 2-(2,4-dichloro-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one · Evolus · Milestone
Code names: DPX-R6447

Resolves to

Compound

UNIIXQK9668H5MCAS68049-83-2ChEBI2943KEGGC10895

Structure

InChIKeyXOEMATDHVZOBSG-UHFFFAOYSA-NSMILESClC1=CC(Cl)=C(C=C1OCC#C)N1N=C2CCCCN2C1=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Azafenidin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account